According to Bloomberg, the eleven analysts who follow Bayer Aktiengesellschaft (OTCMKTS: BAYRY) gave the stock a “moderate buy” rating, which is the group’s overall recommendation for the stock. This rating corresponds to the group’s overall recommendation for the title. Additionally, financial analysts made ten recommendations to buy stocks, while only one recommendation was made to hold the stock. The 1-year average target price that brokers who have hedged the stock over the past year have set is $85.00.
Deposit $100 and get $110 to trade stocks
>>>>>>>>>>Open an account
Recent events have prompted several stock analysts to offer their views on the company’s stock price. In a research note published Wednesday, August 31, JPMorgan Chase & Co. raised its price target on shares of Bayer Aktiengesellschaft from €75.00 ($76.53) to €80.00 ($81.63) in a research note. Moreover, they called the company “overweight”. In a research report published on September 7, Morgan Stanley lowered its price target on shares of Bayer Aktiengesellschaft from €87.00 ($88.78) to €80.00 ($81.63) and maintained a “overweight” rating on the stock. In a research note published on Tuesday August 30, Exane BNP Paribas announced that it was changing its recommendation on Bayer Aktiengesellschaft shares from “neutral” to “outperform” in a research note. In a research note published on Tuesday, August 16, Deutsche Bank Aktiengesellschaft raised its price target on shares of Bayer Aktiengesellschaft from €75.00 ($76.53) to €79.00 ($80.61) and classified the company as a “buy”. This was the latest positive news regarding the latest track from
When trading began on Friday, BAYRY’s stock price was $11.59 per share. There is a leverage ratio of one (1), a quick ratio of 0.84 and a current ratio of 1.18. The three ratios are equal. Additionally, the company has a price-to-earnings ratio of 9.42, a price-to-earnings-to-growth ratio of 1, and a beta value of 1.09. The market capitalization of the company is $45.55 billion. The stock hit a 52-week low at $11.41 during the year, while it hit a 52-week high at $18.45. The company’s moving average is $13.06 over the past 50 days and $15.20 over the past 200 days.
On Thursday, August 4, Bayer Aktiengesellschaft (OTCMKTS: BAYRY) released the results of its latest quarterly earnings report, officially kicking off August. The company’s earnings per share for the quarter came in at $0.51, $0.05 higher than analysts’ average expectation of $0.46 for earnings per share in the quarter. The company’s final quarter revenue was $13.66 billion, significantly higher than the average revenue forecast of $12.28 billion for the final quarter of this year. society. Bayer Aktiengesellschaft’s return on equity was 21.56%, while the company’s net margin was 8.84%. Both of these figures are in percentages. Market watchers believe Bayer Aktiengesellschaft will make 2.03 euros per share in profit for the current financial year.
Bayer Aktiengesellschaft and all of its subsidiaries and affiliates form an important player in the global life sciences industry. The company strongly emphasizes crop science, consumer health and medicine as its three main areas of business. The pharmaceutical industry manufactures specialty drugs for oncology, hematology and ophthalmology. It also manufactures diagnostic imaging equipment and contrast agents, cell and gene therapies and specialty therapies for oncological, hematological and ophthalmological conditions.